Finally, investigations have demonstrated that genomic ctDNA profiling from a blood sample can give insight into the biology of BRAF mutants in NSCLC patients, as well as predict what mechanism is involved [85]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.